Kowa has been granted a patent for a medicinal composition combining a PPAR a agonist and an SGLT2 inhibitor to prevent and treat nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. The method includes administering pemafibrate and tofogliflozin to affected patients. GlobalData’s report on Kowa gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kowa, Eye-tracking wearables was a key innovation area identified from patents. Kowa's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Medicinal composition for treating liver diseases
A recently granted patent (US12042483B2) outlines a novel method for treating various liver diseases, including nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. The method involves administering therapeutically effective amounts of two specific compounds: pemafibrate and tofogliflozin, or their pharmaceutically acceptable salts. The claims emphasize that these compounds, when used in combination, are effective in treating the specified liver diseases in human subjects, with the potential to improve liver health significantly.
Additionally, the patent includes claims focused on reducing lipid droplet size and ballooning in the liver, which are common pathological features associated with the aforementioned liver diseases. The same combination of pemafibrate and tofogliflozin is proposed for this purpose, reinforcing the therapeutic potential of these compounds. The claims specify that the methods can be applied to patients diagnosed with any of the listed liver conditions, highlighting the versatility of this treatment approach in addressing multiple liver-related health issues.
To know more about GlobalData’s detailed insights on Kowa, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
